245 related articles for article (PubMed ID: 30633929)
1. Preclinical safety and efficacy of cannabidivarin for early life seizures.
Huizenga MN; Sepulveda-Rodriguez A; Forcelli PA
Neuropharmacology; 2019 Apr; 148():189-198. PubMed ID: 30633929
[TBL] [Abstract][Full Text] [Related]
2. Cannabidivarin is anticonvulsant in mouse and rat.
Hill AJ; Mercier MS; Hill TD; Glyn SE; Jones NA; Yamasaki Y; Futamura T; Duncan M; Stott CG; Stephens GJ; Williams CM; Whalley BJ
Br J Pharmacol; 2012 Dec; 167(8):1629-42. PubMed ID: 22970845
[TBL] [Abstract][Full Text] [Related]
3. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
Hill TD; Cascio MG; Romano B; Duncan M; Pertwee RG; Williams CM; Whalley BJ; Hill AJ
Br J Pharmacol; 2013 Oct; 170(3):679-92. PubMed ID: 23902406
[TBL] [Abstract][Full Text] [Related]
4. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.
Iannotti FA; Hill CL; Leo A; Alhusaini A; Soubrane C; Mazzarella E; Russo E; Whalley BJ; Di Marzo V; Stephens GJ
ACS Chem Neurosci; 2014 Nov; 5(11):1131-41. PubMed ID: 25029033
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
6. Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
Thornton C; Dickson KE; Carty DR; Ashpole NM; Willett KL
Epilepsy Behav; 2020 Sep; 110():107152. PubMed ID: 32585475
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures.
Brodie MJ; Czapinski P; Pazdera L; Sander JW; Toledo M; Napoles M; Sahebkar F; Schreiber A;
Cannabis Cannabinoid Res; 2021 Dec; 6(6):528-536. PubMed ID: 33998885
[No Abstract] [Full Text] [Related]
8. Preclinical efficacy of cannabidiol for the treatment of early-life seizures.
Witherspoon E; Quinlan S; Forcelli PA
Pharmacol Rep; 2022 Oct; 74(5):1092-1098. PubMed ID: 36220975
[TBL] [Abstract][Full Text] [Related]
9. Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.
Amada N; Yamasaki Y; Williams CM; Whalley BJ
PeerJ; 2013; 1():e214. PubMed ID: 24282673
[TBL] [Abstract][Full Text] [Related]
10. Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats.
Huizenga MN; Wicker E; Beck VC; Forcelli PA
Epilepsia; 2017 Sep; 58(9):1593-1602. PubMed ID: 28691158
[TBL] [Abstract][Full Text] [Related]
11. Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male
Zamberletti E; Gabaglio M; Piscitelli F; Brodie JS; Woolley-Roberts M; Barbiero I; Tramarin M; Binelli G; Landsberger N; Kilstrup-Nielsen C; Rubino T; Di Marzo V; Parolaro D
J Psychopharmacol; 2019 Jul; 33(7):894-907. PubMed ID: 31084246
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.
Hurley EN; Ellaway CJ; Johnson AM; Truong L; Gordon R; Galettis P; Martin JH; Lawson JA
Epilepsia; 2022 Jul; 63(7):1736-1747. PubMed ID: 35364618
[TBL] [Abstract][Full Text] [Related]
13. The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?
Löscher W
Neurochem Res; 2017 Jul; 42(7):1926-1938. PubMed ID: 27502939
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).
Klein BD; Jacobson CA; Metcalf CS; Smith MD; Wilcox KS; Hampson AJ; Kehne JH
Neurochem Res; 2017 Jul; 42(7):1939-1948. PubMed ID: 28478594
[TBL] [Abstract][Full Text] [Related]
15. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients.
Pagano E; Romano B; Iannotti FA; Parisi OA; D'Armiento M; Pignatiello S; Coretti L; Lucafò M; Venneri T; Stocco G; Lembo F; Orlando P; Capasso R; Di Marzo V; Izzo AA; Borrelli F
Pharmacol Res; 2019 Nov; 149():104464. PubMed ID: 31553934
[TBL] [Abstract][Full Text] [Related]
16. Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats.
Zamberletti E; Gabaglio M; Woolley-Roberts M; Bingham S; Rubino T; Parolaro D
Front Cell Neurosci; 2019; 13():367. PubMed ID: 31447649
[TBL] [Abstract][Full Text] [Related]
17. Unravelling a novel role for cannabidivarin in the modulation of subventricular zone postnatal neurogenesis.
Lourenço DM; Soares R; Sá-Santos S; Mateus JM; Rodrigues RS; Moreira JB; Vaz SH; Sebastião AM; Solá S; Xapelli S
Eur J Pharmacol; 2023 Nov; 959():176079. PubMed ID: 37802277
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome.
Vigli D; Cosentino L; Raggi C; Laviola G; Woolley-Roberts M; De Filippis B
Neuropharmacology; 2018 Sep; 140():121-129. PubMed ID: 30056123
[TBL] [Abstract][Full Text] [Related]
19. Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels.
Vilela LR; Lima IV; Kunsch ÉB; Pinto HPP; de Miranda AS; Vieira ÉLM; de Oliveira ACP; Moraes MFD; Teixeira AL; Moreira FA
Epilepsy Behav; 2017 Oct; 75():29-35. PubMed ID: 28821005
[TBL] [Abstract][Full Text] [Related]
20. Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood-Brain Barrier Under Ischemic Conditions.
Stone NL; England TJ; O'Sullivan SE
Cannabis Cannabinoid Res; 2021 Aug; 6(4):315-326. PubMed ID: 33998890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
